WO2023057371 - 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2023/057371
Publication Date
13.04.2023
International Application No.
PCT/EP2022/077442
International Filing Date
03.10.2022
Title **
[English]
1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER
[French]
DÉRIVÉS DE 1,2,4-OXADIAZOL-5-ONE POUR TRAITER LE CANCER
Applicants **
BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL
Hegenheimermattweg 167b
4123 Allschwil, CH
Inventors
RICHALET, Florian
Basilea Pharmaceutica International AG, Allschwil
Hegenheimermattweg 167b
4123 Allschwil, CH
Priority Data
21200757.9
04.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1359 | |
| EPO | Filing, Examination | 7601 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 11310 |
Total: 21439 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
- may be replaced by -N(R3)- or -O- and wherein Y may be substituted by one -OH on a carbon atom that is not bound to an oxygen atom or a nitrogen atom, and R2 and R3 are as defined in the claims; as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.[French]
- peut être remplacée par -N(R3)- ou -O- et Y peut être substitué par un -OH sur un atome de carbone qui n'est pas lié à un atome d'oxygène ou à un atome d'azote, et R2 et R3 sont tels que définis dans les revendications; ainsi que des procédés d'utilisation des composés pour traiter des maladies néoplasiques, en particulier le cancer.